| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Stevanato Group S.p.A.$20.2
-0.21 (-1.03%)
Market Cap
4.92 B
EPS
0.60
P/E Ratio
29.98 $
Value Trade
8.78 M
1.92 %
Week
16.49 %
1 Month
11.45 %
3 Month
-15.13 %
6 Month
8.17 %
5 Year
8.17 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
270.26 K
52 Week Range
12.89 - 28
% held by Insiders
81.79 %
% held by Institutions
17.08 %
Enterprise Value
5.30 B
Total Shares
49.70 M
Short %
1.94 %
Float Shares
48.95 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in STVN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
STVN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
STVN▼ -1%today
Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries
Stevanato Group S.p.A. announced that its liraglutide-based combination products, utilizing the Alina® pen injector, have received marketing authorizations across several European countries. This development signifies a notable expansion for the company in the European pharmaceutical market. The authorizations pertain to finished combination products held by respective marketing entities.
Read more →STVNStevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026
Stevanato Group S.p.A. will release its financial results for Q2 2026 on August 4, 2026. The announcement includes details about a conference call and webcast scheduled for the same day at 8:30 a.m. (EDT). This event will provide insights into the company's performance and future outlook.
Read more →STVNStevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management
Stevanato Group has launched Deora™, a pen injector designed for subcutaneous delivery. This device targets diabetes and weight management, aiming to enhance patient experience. The introduction of Deora™ reflects the company's commitment to innovative healthcare solutions.
Read more →STVNStevanato Group Announces Results of Ordinary and Extraordinary Shareholders’ Meeting
Stevanato Group held an ordinary and extraordinary shareholders' meeting. The details of the results or decisions made during the meeting were not disclosed in the article. The announcement indicates ongoing corporate governance activities.
Read more →STVNStevanato Group Announces Results of Ordinary and Extraordinary Shareholders' Meeting All Resolutions Proposed to Shareholders Passed Piombino Dese, Italy, June 3rd, 2026. Stevanato Group S.p.A. (NYSE: STVN
Stevanato Group S.p.A. held its Ordinary and Extraordinary Shareholders' Meeting on June 3rd, 2026, in which all proposed resolutions were approved. Shareholders granted new authorizations for share purchases and amendments to the Company's By-laws to facilitate corporate rights and governance. A new Board of Directors was appointed, alongside the approval of PricewaterhouseCoopers S.p.A. as the external auditor for financial statements up to the end of 2028. Additionally, a dividend of EUR 0.054 was approved for each share.
Read more →STVNPublished on
Stevanato Group S.p.A. will hold its Ordinary and Extraordinary General Meeting of Shareholders on May 26, 2026, via teleconference. Shareholders holding ordinary shares on the Record Date have rights to attend and vote, while beneficial owners must follow specific procedures to record their votes. The meeting will cover the appointment of members to the Board of Directors among other agenda items, emphasizing adherence to the Company's Bylaws and relevant civil codes.
Read more →STVN▼ -5.1%on this newsshared move
Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026
Stevanato Group reported a 7% revenue growth for Q1 2026, reaching €273.6 million, with high-value solutions accounting for 47% of total revenue. The Biopharmaceutical and Diagnostic Solutions segment drove this growth with a 13% increase. Despite a decline in the Engineering Segment, the company maintained its fiscal guidance for the year, expecting revenue between €1.26 billion and €1.29 billion.
Read more →STVN▼ -5.1%on this newsshared move
Stevanato Group S.p.A. "First Quarter 2026 Financial Results Conference Call" Thursday
Stevanato Group S.p.A. held its First Quarter 2026 Financial Results Conference Call, reporting a 10% revenue growth driven by demand for pre-fillable syringes and biologics. The company highlighted strong performance in the Biopharmaceutical and Diagnostic Solutions segment, while acknowledging a revenue decline in the Engineering Segment due to low order intake. Key projects in the U.S. and Italy are on schedule, and operational improvements are being pursued. The call also noted that the CEO is currently recovering from an unexpected medical procedure.
Read more →STVN▼ -5.1%on this newsshared move
Q1 2026 Financial Results Safe Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that ref
Stevanato Group's Q1 2026 financial results presentation includes forward-looking statements that caution about various risks and uncertainties affecting the company's future performance. Key concerns include potential interruptions in operations, the complexities of product offerings, intense competition for skilled employees, and geopolitical factors that could negatively impact business. The statements emphasize that actual results may differ materially from the predictions made due to these various risks.
Read more →STVN▼ -5.1%on this newsshared move
Free Cash Flow (Amounts in € millions) For the three months ended
Stevanato Group S.p.A. reported a 7% increase in revenue for the first quarter of 2026, reaching €273.6 million, supported by growth in its Biopharmaceutical and Diagnostic Solutions segment. The company's adjusted EBITDA margin improved to 23.9%, reflecting operational efficiencies. Despite revenue declines in the Engineering Segment and challenges with depreciation, Stevanato maintains its fiscal guidance for the year, anticipating total revenue between €1.26 billion and €1.29 billion. The CEO expressed confidence in the company's strategic investments and focus on high-value solutions.
Read more →STVNStevanato Group to Participate in Three Upcoming Investor Conferences
Stevanato Group is set to participate in three upcoming investor conferences. The details regarding the specific conferences and their dates were not provided in the article. This participation indicates the company's ongoing engagement with investors and stakeholders.
Read more →STVNStevanato Group to Report First Quarter 2026 Financial Results on May 7, 2026
Stevanato Group S.p.A. will release its financial results for Q1 2026 on May 7, 2026, at 6:30 a.m. EDT. A conference call and webcast will follow at 8:30 a.m. EDT, where management will discuss the results. Participants can pre-register for immediate access and will have the opportunity to ask questions during the call.
Read more →STVNStevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum
Stevanato Group S.p.A. will participate in the KeyBanc Capital Markets Virtual Healthcare Forum on March 17-18, 2026. The company is set to present on March 17 from 9:45 to 10:20 a.m. ET, with a live webcast available on its website. A replay of the event will be accessible for 90 days post-forum.
Read more →STVN▲ +18.8%on this news
Stevanato Group Delivers 7% Revenue Growth (9% at Constant Currency) for Fiscal Year 2025, Including Record Revenue from High-Value Solutions and Expanded Margins
Stevanato Group reported a 7% revenue growth for fiscal year 2025, reaching €1.186 billion, with high-value solutions contributing significantly. The fourth quarter saw a 5% revenue increase, driven by strong performance in the Biopharmaceutical and Diagnostic Solutions Segment. The company anticipates continued growth in fiscal 2026, projecting revenue between €1.26 billion and €1.29 billion.
Read more →STVN▲ +18.8%on this newsshared move
Free Cash Flow (Amounts in € millions) For the three months ended December 31, For the years ended
Stevanato Group S.p.A. reported a 7% revenue growth for fiscal year 2025, driven by a strong performance in its Biopharmaceutical and Diagnostic Solutions segment. The company's high-value solutions represented a significant portion of total revenue. Despite challenges in the Engineering Segment and adverse effects from currency fluctuations, the company established an optimistic guidance for fiscal 2026 with expected revenue between 1.26 billion to 1.29 billion euros. The CEO highlighted continued momentum in the biologics market as a primary growth driver moving forward.
Read more →STVN▲ +18.8%on this newsshared move
Q4 and FY 2025 Financial Results Safe Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 t
Stevanato Group has released its Q4 and FY 2025 financial results, outlining various forward-looking statements that reflect both growth expectations and potential risks. The company anticipates an expansion of its operations, aiming to enhance profitability despite uncertainties from economic conditions and global conflicts. Key risks include the need for new product development, competition for skilled employees, and maintaining supplier relationships amid a volatile market. The firm aims to navigate these challenges while optimizing its operational capabilities.
Read more →STVN▲ +18.8%on this newsshared move
Stevanato Group S.p.A. Fourth Quarter and Full Year 2025 Financial Results Conference Call Wednesday
Stevanato Group S.p.A. reported its Fourth Quarter and Full Year 2025 financial results, highlighting a 9% increase in total revenue for the year. The Biopharmaceutical and Diagnostic Solutions segment showed robust growth, offsetting declines in the Engineering segment. Looking ahead, the company provided guidance for 2026, expecting growth in its BDS segment but forecasting a decline in Engineering revenues due to several anticipated challenges including foreign currency impacts. The overall outlook remains positive, supported by strong market demand for innovative drug products.
Read more →STVNStevanato Group to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 4, 2026
Stevanato Group S.p.A. will release its financial results for Q4 and fiscal year 2025 on March 4, 2026. A conference call and webcast will follow at 8:30 a.m. (ET) to discuss these results. Participants can pre-register for immediate access, and a replay will be available for three months on the company's website.
Read more →STVNFree Cash Flow (Amounts in € millions) For the three months ended September 30, For the nine months ended
Stevanato Group S.p.A. reported a 9% revenue increase for Q3 2025, reaching 303.2 million. High-value solutions, primarily driven by Nexa syringes, constituted a record 49% of total revenue. The company maintained its fiscal 2025 guidance despite challenges in the Engineering Segment and ongoing tariff and currency impacts. Overall, strong performance in the Biopharmaceutical and Diagnostic Solutions segment underscored the effectiveness of their strategic investments and capacity expansions.
Read more →STVNStevanato Group S.p.A. Third Quarter 2025 Financial Results Conference Call Thursday
Stevanato Group S.p.A. announced its financial results for the third quarter of 2025, showcasing a 9% revenue growth year-over-year, primarily driven by the strong performance of its BDS segment, which grew by 14%. Despite facing challenges from currency fluctuations and a decline in the engineering segment, the company remains confident about meeting its 2025 guidance and expects continued demand for high-value drug containment solutions. Stevanato's commitment to investment and innovation is underlined by a recent recognition for sustainability performance, reflecting a strategic focus on growth in the biologics market.
Read more →STVNQ3 2025 Financial Results Safe Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that ref
Stevanato Group's Q3 2025 financial results presentation includes forward-looking statements regarding their anticipated financial performance and operational capabilities. The company remains optimistic about expanding their capacity and effectively responding to market demand despite known and unknown risks. Key concerns highlighted include dependency on supplier relationships, the impact of geopolitical tensions, and heightened competition. The presentation emphasizes caution regarding the unpredictability of future outcomes influenced by these factors.
Read more →STVN▼ -9.7%on this news
Stevanato Group S.p.A. Second Quarter 2025 Results Conference Call Tuesday
Stevanato Group S.p.A. released its second quarter 2025 results, reporting an 8% revenue growth driven by strong performance in its Biopharmaceutical and Diagnostic Solutions Segment. High-value solutions constituted 42% of total revenue, reflecting the demand for premium products, although the Engineering Segment saw a 2% decline. The company is making operational progress on its optimization plan, with significant improvements in customer acceptance tests and ongoing capital investments to meet market demands.
Read more →STVN▼ -9.7%on this news
Q2 2025 Financial Results Safe Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that ref
Stevanato Group announced its Q2 2025 financial results, highlighting a commitment to future growth despite significant uncertainties. The company's forward-looking statements outline expectations for revenue, operational performance, and capacity expansion. However, these optimistic views are tempered by risks including global economic conditions, supply chain challenges, and reliance on product quality. Additionally, potential disruptions from geopolitical factors and market competition may impact their financial outlook.
Read more →STVN▼ -9.7%on this news
Free Cash Flow (Amounts in € millions) For the three months ended June 30, For the six months ended
Stevanato Group S.p.A. reported financial results for Q2 2025, showcasing an 8% year-over-year revenue growth, reaching €280 million. The company's gross profit margin expanded to 28.1%, bolstered by demand for high-value solutions. While the Biopharmaceutical and Diagnostic Solutions segment performed strongly, the Engineering Segment faced a revenue decline. The company maintains its fiscal year 2025 guidance amidst these mixed financial results.
Read more →STVN▲ +5.5%on this news
Stevanato Group Announces Results of Ordinary Shareholders Meeting
Stevanato Group S.p.A. announced that all resolutions proposed at its recent Ordinary Shareholders Meeting were successfully passed. Key approvals included the annual financial statements and the distribution of a EUR 0.054 dividend for shareholders. The company also appointed a new Board of Directors and approved increased compensation for its auditing firm. Additionally, a new authorization for the repurchase and disposal of shares was granted, reflecting strategic financial management.
Read more →STVNStevanato Group S.p.A. First Quarter 2025 Results Conference Call Tuesday
Stevanato Group S.p.A. reported strong financial results for the first quarter of 2025, with a 9% increase in revenue, driven mainly by robust performance in the Biopharmaceutical and Diagnostic Solutions segment. The company's gross profit margin also improved, attributed to scaling operations in their Latina and Fishers facilities. However, there was a noted decline in the Engineering segment, primarily linked to legacy projects. The company remains optimistic about future revenue growth and market demand for high-value solutions.
Read more →STVNQ1 2025 Financial Results Safe Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that ref
Stevanato Group has released its Q1 2025 financial results, highlighting a cautious outlook influenced by several forward-looking statements. The company describes various factors that may impact its future performance, including global economic conditions, inflation, and operational risks. Management indicates optimism regarding capacity expansion and financial stability; however, it acknowledges significant uncertainties and competitive challenges ahead.
Read more →STVNFree Cash Flow (Amounts in € millions) For The Three Months Ended
Stevanato Group S.p.A. reported a revenue increase of 9% to €256.6 million for Q1 2025, driven primarily by growth in its Biopharmaceutical and Diagnostic Solutions Segment. The high-value solutions category represented 43% of total revenue, benefiting from strong customer demand and capacity expansions. However, the Engineering Segment saw a 4% decline in revenue, and the company updated its guidance to reflect potential tariff impacts on profitability. Despite these headwinds, the company remains optimistic about its long-term growth potential in the market.
Read more →STVN▲ +8.6%on this news
Stevanato Group S.p.A. Fourth Quarter and Year-End 2024 Conference Call Thursday
Stevanato Group S.p.A. has announced it will hold a conference call to discuss its Fourth Quarter and Year-End 2024 results. The call is scheduled for March 6, 2025, at 14:30 AM CET, featuring Chief Financial Officer Marco Dal Lago and Senior Vice President Lisa Miles. This event will likely provide insights into the company's financial performance and future outlook.
Read more →STVN▲ +8.6%on this news
Q4 and FY 2024 Financial Results Safe Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 t
Stevanato Group has released its Q4 and FY 2024 financial results, highlighting significant forward-looking statements that reflect both opportunities and risks. The company emphasizes its strategies to enhance production capacity and maintain profitability amidst a changing industry landscape. However, it also acknowledges numerous uncertainties, including global economic conditions and potential supply chain issues, which could materially impact its future performance. Additionally, the firm must navigate increased competition and the challenges of product development in a complex regulatory environment.
Read more →STVN▲ +8.6%on this news
Amounts may not add due to rounding stevanatogroup.com Stevanato Group S.p.A. Ph. +39 049 931 8111 Via Molinella, 17 - 35017 Piombino Dese, Padova, Italy F. +39 049 936 6151 Cap. Soc. € 22.231.562,00 i.v. - C.f. e
Stevanato Group S.p.A. reported significant financial results for the fourth quarter and full year of 2024, highlighting a record revenue of 1,104 million. Despite this success, the company faced challenges with a 16% decline in its Engineering Segment and lower gross profit margins attributed to vial destocking. Looking ahead, Stevanato is optimistic, introducing guidance for fiscal year 2025 with expected revenue growth and improved earnings per share. The company's focus remains on scaling production to meet the growing demand for high-value solutions in the pharmaceutical sector.
Read more →STVN▲ +16.1%on this news
Q3 2024 Financial Results Safe Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that ref
Stevanato Group has released its Q3 2024 financial results alongside a forward-looking statement outlining potential risks and uncertainties affecting its business. The company addresses various factors including economic conditions, customer demand, and operational challenges that could materially alter its performance expectations. Specific challenges include the need to maintain product quality, manage employee retention, and navigate global supply chain issues. The reliance on several critical components and the ambiguity in future market conditions highlight the inherent risks associated with their growth strategy.
Read more →STVN▲ +16.1%on this news
Stevanato Group S.p.A. Third Quarter 2024 Earnings Call Tuesday
Stevanato Group S.p.A. held its third-quarter earnings call for 2024, where key financial results were discussed. The company reported a revenue increase of 2%, but margins fell short of expectations, resulting in lowered guidance for adjusted EBITDA and EPS. Despite these challenges, Stevanato highlighted growth in the high-value solutions segment and ongoing progress in their optimization plan aimed at improving business performance. The company anticipates stabilization in vial demand and is cautious about the near-term outlook.
Read more →STVN▲ +5.7%on this news
Q2 2024 Financial Results Safe Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that ref
Stevanato Group's Q2 2024 financial presentation highlights forward-looking statements that detail the company's expected growth and challenges. While the organization aims to expand its production capacity and leverage its product portfolio, it faces uncertainties in product quality, competition for skilled employees, and geopolitical risks. Additionally, there are concerns about the sustainability of revenue growth following the increased demand from COVID-19 related products.
Read more →STVN▲ +5.7%on this news
Stevanato Group S.p.A. Second Quarter 2024 Earnings Call Tuesday
Stevanato Group S.p.A. is set to hold its earnings call for the second quarter of 2024 on August 6, 2024, at 14:30 CET. The call will feature Lago, the Chief Financial Officer, and Miles, the Senior Vice President of Investor Relations, discussing the company's financial performance and outlook. This event is an opportunity for stakeholders to gain insights into the company's developments during the quarter.
Read more →STVNStevanato Group Appoints Franco Stevanato Chief Executive Officer, Succeeding Franco Moro
Stevanato Group has appointed Franco Stevanato as its new Chief Executive Officer, succeeding Franco Moro, who will remain on the Board until June 30, 2024. Franco Stevanato, previously Executive Chairman, has a long history with the company and is credited with driving its global expansion and product diversification. The transition reflects the company’s confidence in Stevanato’s leadership to enhance its strategic initiatives and operational efficiencies in the pharmaceutical industry.
Read more →STVNStevanato Group Announces Results of Annual General Meeting -All Resolutions Proposed to Shareholders Passed
Stevanato Group S.p.A. announced that all resolutions proposed at its Annual General Meeting held on May 22, 2024, were approved by shareholders. Key approvals included the annual financial statements for 2023 and a dividend distribution of EUR 0.053 per share. The company appointed a new Board of Directors, maintaining a mix of returning members and introducing new faces. Detailed information about the AGM resolutions and outcomes is available on the company’s official website.
Read more →STVN▼ -21.6%on this newsshared move
Stevanato Group S.p.A. First Quarter 2024 Earnings Call Thursday
Stevanato Group S.p.A. held its first quarter 2024 earnings call, detailing the company's current challenges and operational strategies. The company acknowledged that first quarter results fell short of expectations primarily due to a temporary destocking in the vials market and a postponement of key customer orders. Despite these challenges, Stevanato remains optimistic about its long-term growth prospects, emphasizing a robust demand landscape in biologics. The company is focused on optimizing operations and ramping up high-value solution capacity to meet future customer demand.
Read more →STVN▼ -21.6%on this newsshared move
Q1 2024 Financial Results Safe Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that ref
Stevanato Group's Q1 2024 financial results presentation highlights various forward-looking statements regarding the company's future performance. These include growth expectations in revenue by expanding production capacity and adapting to technological changes. However, the company also acknowledges significant risks, including product quality issues and intense competition for talent. It emphasizes the importance of maintaining strong supplier relationships and effective internal controls to support its operational success.
Read more →STVNStevanato Group Announces Closing of Upsized Public Offering of Ordinary Shares and Exercise in Full of the Underwriters Option to Purchase Additional Ordinary Shares
Stevanato Group has successfully completed an upsized public offering, selling a total of 14,605,000 ordinary shares. This includes a full exercise of the underwriters' option to purchase additional shares, fetching gross proceeds of around $379.7 million. The company plans to utilize the net proceeds for general corporate purposes, enhancing its operational and strategic capabilities. The offering was part of an automatic shelf registration and was well-received in the market.
Read more →STVNStevanato Group Announces Pricing of Upsized Public Offering of Ordinary Shares
Stevanato Group has announced the pricing of its upsized public offering, selling 12,700,000 ordinary shares at a price of $26.00 each. The offering is expected to generate gross proceeds of around $330 million, which will be utilized for general corporate purposes, including supporting ongoing investments. The completion of the offering is anticipated on March 26, 2024, contingent on customary closing conditions. Notably, the offering includes shares from a major shareholder in addition to those from the company itself.
Read more →STVN▼ -5.2%on this newsshared move
Stevanato Group Announces Public Offering of Ordinary Shares
Stevanato Group announced a public offering of ordinary shares worth $300 million, split equally between its own offering and that of a major shareholder. The proceeds are intended for general corporate purposes and to support ongoing investment activities. Morgan Stanley and William Blair are acting as joint book-running managers for this offering. This move reflects the company’s strategy to enhance operational flexibility, although it does bring inherent risks related to market conditions and successful completion of the offering.
Read more →STVN▼ -8.2%on this news
Stevanato Group S.p.A. Fourth Quarter and Year-End 2023 Financial Results Earnings Call Thursday
Stevanato Group S.p.A. has released its financial results for the fourth quarter and year-end 2023, reporting a 10% growth in revenue. Despite facing challenges from macroeconomic factors such as inflation and customer destocking, the company successfully advanced capacity expansion projects. The demand for high-value solutions is expected to continue driving growth, although recent results reflected lower-than-expected metrics primarily due to a decline in COVID-19 related sales. Management remains focused on executing strategies to enhance long-term shareholder value.
Read more →STVN▼ -8.2%on this news
Q4 and FY 2023 Financial Results Safe Harbor Statement Forward-Looking Statements This presentation may include forward-looking statements. The words executing, advancing, solid, positive, benefitting, continue, drive, e
Stevanato Group reported positive financial results for Q4 and the full year 2023, highlighting a solid 10% revenue growth despite a challenging market characterized by inflation and supply chain issues. The company successfully executed capacity expansion projects and maintained a strong market position, particularly in high-growth areas like biologics. However, there were slight misses in revenue expectations for Q4, reflecting a reduction in profit margins compared to the previous year. Moving forward, the company forecasts robust growth, targeting 9% to 12% revenue growth for FY 2024.
Read more →STVNStevanato Group S.p.A. Third Quarter 2023 Financial Results Conference Call Tuesday
Stevanato Group S.p.A reported its third quarter 2023 financial results, showcasing an 11% increase in revenue, although this was below prior expectations for the Engineering segment. The company maintains a strong adjusted EBITDA margin of 27.5% and reaffirms its full year guidance. Factors such as a shift in revenue timing for certain Engineering contracts and a revenue headwind in the BDS segment were highlighted as challenges. Nevertheless, the company remains optimistic about its long-term growth, particularly in biologics.
Read more →STVNForward-Looking Statements This presentation may include forward-looking statements. The words expect,” reiterating,” “continue,” “assumes, rise, “position,” strong, incre
Stevanato Group reported its Q3 2023 financial results, showcasing a double-digit revenue growth of 16% year-over-year. While they achieved an adjusted EBITDA margin of 27.5%, the engineering segment's revenue was below expectations due to timing issues, with some projects delayed and anticipated revenue now expected in Q4. The overall business fundamentals remain strong, benefiting from shifts in the biopharma sector and the company's strategic focus on biologics and biosimilars.
Read more →STVNStevanato Group Reports Third Quarter 2023 Financial Results - Reiterates Full Year 2023 Guidance- PIOMBINO DESE, Italy –
Stevanato Group S.p.A. reported its third quarter financial results for 2023, highlighting a revenue increase of 11% compared to the previous year, totaling $271.4 million. The company continues to focus on its high-value solutions, which now account for 32% of its revenue. Despite a decline in revenue from Covid-19 related products, the company is maintaining its full year guidance and remains optimistic about future growth driven by demand in biologics and new manufacturing capabilities.
Read more →STVNStevanato Group Announces Voting Results from its Extraordinary General Meeting PIOMBINO DESE (PD), Italy
Stevanato Group S.p.A. announced the successful approval of a resolution during its Extraordinary General Meeting held on October 4, 2023. Shareholders delegated the Board of Directors the authority to increase share capital by up to €350 million, which can be executed in one or more tranches. This move is expected to strengthen the company’s financial position and support future growth strategies.
Read more →STVN▲ +8.5%on this news
Lisa Miles x Investor Relations, Senior Vice President Welcome Capital Markets Day
On September 27, 2023, Stevanato Group hosted a Capital Markets Day led by Senior Vice President Lisa Miles. The agenda included discussions on future growth, industry outlook, and financial updates. The company is focusing on expanding production capacity and ensuring innovation amid tight competition and global economic challenges. Forward-looking statements highlighted both growth opportunities and potential risks facing the company.
Read more →STVNStevanato Group S.p.A. Extraordinary Shareholders Meeting
Stevanato Group S.p.A. convened an extraordinary shareholders meeting on October 4, 2023, to discuss a proposed delegation to the Board of Directors for a share capital increase of up to Euro 350 million. This delegation aims to enhance financial flexibility by allowing timely capital raising in response to market conditions. The proposal includes excluding existing shareholders' pre-emptive rights, thereby broadening the company’s investor base.
Read more →STVNSummary of Resolutions Passed at Annual General Meeting on
On May 24, 2023, Stevanato Group S.p.A. (NYSE: STVN) held its Annual General Meeting, during which all proposed resolutions were successfully approved by shareholders. Key approvals included financial statements for the fiscal year ending December 31, 2022, and a dividend distribution of EUR 0.054 per share. Shareholders also appointed PricewaterhouseCoopers S.p.A. as the external auditor for the next three financial years and granted the board new authorization for treasury share transactions. Additionally, proposed amendments to the company's articles of association were ratified.
Read more →STVNStevanato Group S.p.A. Second Quarter 2023 Financial Results Conference Call Friday
Stevanato Group S.p.A. reported solid second quarter financial results with a 9% year-over-year revenue increase, driven by strong demand in its high value EZ-fill products. Approximately 33% of total revenue came from high value solutions, marking an improvement from the previous year. The company aims for continued growth in the biologics market, which shows promising projections moving forward. The management highlighted ongoing expansion efforts and a robust strategy to meet customer demand in growing end markets.
Read more →STVNStevanato Group Reports Second Quarter 2023 Financial Results - Reiterates Full Year 2023 Revenue and Adjusted Diluted Earnings per Share Guidance; Increases Adjusted EBITDA Guidance - PIOMBINO DESE, Italy –
Stevanato Group S.p.A. reported a 9% revenue increase for Q2 2023, totaling $255.3 million, driven by demand for high-value solutions. While the company reiterated its full-year guidance for revenue and adjusted diluted EPS, it increased its adjusted EBITDA guidance to between $291.8 million and $303.8 million. Notably, there was a significant drop in revenue related to Covid-19, which fell to just 1% of total revenue. Despite slight declines in profit margins due to start-up costs, the company remains optimistic about organic revenue growth in biologics.
Read more →STVNForward-Looking Statements This presentation may include forward-looking statements. The words expect,” reiterating,” “durable,” “continue,” “shifting,” “exp
Stevanato Group reported a solid Q2 2023 performance with a 20% revenue increase compared to the same period last year, excluding Covid-19 related sales. The company is expanding its manufacturing capacity to meet growing demand for high-value solutions, particularly in the biologics market. However, the gross profit margin fell slightly due to inefficiencies and rising industrial costs. The company remains optimistic about long-term growth, backed by its robust pipeline and strategic investments.
Read more →STVNStevanato Group Reports First Quarter 2023 Financial Results - Reiterates Full Year 2023 Guidance - PIOMBINO DESE, Italy –
Stevanato Group S.p.A. reported its financial results for the first quarter of 2023, highlighting a 12% increase in revenue to $238 million compared to the previous year. High-value solutions represented a growing share of revenue, reflecting increased customer demand. The company reaffirmed its guidance for the full year 2023, expecting revenues between $1.085 billion and $1.115 billion. However, revenue related to Covid-19 has significantly declined, affecting overall earnings.
Read more →STVNStevanato Group S.p.A. First Quarter 2023 Financial Results Conference Call Thursday
Stevanato Group S.p.A. reported its financial results for the first quarter of 2023, highlighting a 12% revenue increase, primarily driven by demand for high-value solutions. The company noted a strategic shift towards these products, representing 32% of total revenue. However, there was a significant decline in revenue from COVID-19 related orders. Overall, Stevanato remains optimistic about future growth opportunities in biologics, particularly GLP-1 treatments.
Read more →STVNForward-Looking Statements This presentation may include forward-looking statements. The words "expect," "growing", "favorable," "driving," "remain," "advance," "rising," "durable," "strong," "increasing," "well-position
Stevanato Group has reported its Q1 2023 financial results, highlighting a 12% increase in revenue driven by strong demand for its EZ-fill products. The company is advancing its strategic initiatives to capture opportunities in the rapidly expanding biologics market, particularly in GLP1 treatments. With a robust order intake and a growing backlog, Stevanato is set to enhance its competitive advantage through partnerships and innovations. The company is also expanding its manufacturing capacity to meet future market demands.
Read more →STVN▲ +6.2%on this news
Stevanato Group S.p.A. Fourth Quarter and Fiscal Year 2022 Financial Results Conference Call Thursday
Stevanato Group S.p.A. announced strong financial results for the fourth quarter and fiscal year 2022, highlighting double-digit growth and expanding margins. The company reported that high-value solutions accounted for 30% of its revenue, with an increase in backlog indicating sustained demand. Their focus on investing in production capacity, especially in relation to biologics and advanced drug delivery systems, reflects optimism for continued growth. Management has refined its capital spending plans to prioritize investments in the U.S. and Europe to meet rising demand.
Read more →STVN▲ +6.2%on this news
Stevanato Group Reports Fourth Quarter and Fiscal Year 2022 Financial Results - Establishes Fiscal 2023 Guidance - PIOMBINO DESE, Italy –
Stevanato Group S.p.A. released its financial results for the fourth quarter and full year of 2022, indicating strong overall growth. Fourth quarter revenue rose by 26% to 292.1 million, driven by the company's high-value solutions. For fiscal year 2022, revenue increased by 17% to 983.7 million, leading to positive adjusted EPS figures. The company also announced its guidance for fiscal 2023, expecting revenue to reach between 1.085 billion and 1.115 billion, along with adjusted diluted EPS between 0.58 and 0.62.
Read more →STVN▲ +6.2%on this news
Forward-Looking Statements This presentation may include forward-looking statements. The words "expect," "growth", "drive," "create," "well positioned," "continues," "remain," "estimate," "'deliver", "accelerating", "sus
Stevanato Group reported strong financial results for Q4 and FY2022, highlighting a 17% year-over-year revenue growth and an increase in adjusted EBITDA margin. The company is well positioned to capitalize on favorable market demand, especially in high-value solutions, as it continues to expand its manufacturing capacity in the U.S. and Italy. Future investments are aimed at meeting projected growth in biologics and enhancing production capabilities with market-specific innovations.
Read more →STVNStevanato Group Third Quarter 2022 Financial Results Conference Call Tuesday
Third Quarter 2022 Financial Results Conference Call Tuesday, November 08, 2022, 14:30 ITA M ODERATORS : F RANCO S TEVANATO , E XECUTIVE C HAIRMAN F RANCO M ORO , C HIEF E XECUTIVE O FFICER M ARCO D AL L AGO , C HIEF F INANCIAL O FFICER L ISA M ILES , S ENIOR V ICE P RES
Read more →STVNForward-Looking Statements This presentation may include forward-looking statements. The words "expect," "growth", "rise," "drive," "create," "are managing," "well positioned," "continues," "remain," "estimate," and simi
Stevanato Group Third Quarter 2022 Financial Results November 8th, 2022 Exhibit 99.1 Forward-Looking Statements This presentation may include forward-looking statements. The words "expect," "growth", "rise," "drive," "create," "are managing," "well positioned," "continues," "
Read more →STVNStevanato Group Reports Third Quarter 2022 Financial Results PIOMBINO DESE, Italy –
Stevanato Group Reports Third Quarter 2022 Financial Results PIOMBINO DESE, Italy November 8, 2022 Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences
Read more →STVNSafe-Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of
Second Quarter 2022 Financial Results August 4, 2022 Exhibit 99.1 Safe-Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current
Read more →STVNStevanato Group Reports Second Quarter 2022 Financial Results - Raises Fiscal 2022 Guidance - PIOMBINO DESE, Italy –
Stevanato Group Reports Second Quarter 2022 Financial Results - Raises Fiscal 2022 Guidance - PIOMBINO DESE, Italy August 04, 2022 Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical,
Read more →STVNStevanato Group Second Quarter Financial Results Conference Call Thursday
Second Quarter Financial Results Conference Call Thursday, August 04, 2022, 14:30 ITA M ODERATORS : F RANCO S TEVANATO , C HAIRMAN F RANCO M ORO , C HIEF E XECUTIVE O FFICER M ARCO D AL L AGO , C HIEF F INANCIAL O FFICER L ISA M ILES , S ENIOR V ICE P RESIDENT , I NVESTO
Read more →STVNStevanato Group Announces Voting Results from its Annual General Meeting
Stevanato Group Announces Voting Results from its Annual General Meeting PIOMBINO DESE, Italy June 2, 2022 Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sc
Read more →STVNTranscript 0800 138 2636 | conferencingservice@netroadshow.com www.incommglobal.com Stevanato Earnings Call Monday, 10 May 2021 Lisa Miles Good morning, and thank you for joining us. With me today is Franco Stevanato, ex
Transcript 0800 138 2636 | conferencingservice@netroadshow.com www.incommglobal.com Stevanato Earnings Call Monday, 10 May 2021 Lisa Miles Good morning, and thank you for joining us. With me today is Franco Stevanato, executive chairman; Franco Moro, chief executive officer;
Read more →STVNStevanato Group Reports First Quarter 2022 Financial Results - The Company is Maintaining its Fiscal 2022 Guidance - PIOMBINO DESE, Italy –
Stevanato Group Reports First Quarter 2022 Financial Results - The Company is Maintaining its Fiscal 2022 Guidance - PIOMBINO DESE, Italy May 10, 2022 Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to
Read more →STVNStevanato Group S.p.A. Ordinary and Extraordinary Shareholders Meeting on
Stevanato Group S.p.A. Ordinary and Extraordinary Shareholders Meeting on the items on the agenda This report (the Explanatory Report ) was drafted by the board of directors of Stevanato Group S.p.A. (respectively, the Board of Directors and Stevanato or the Company ) in rela
Read more →STVNservice@incommglobal.com Transcript www.incommglobal.com Stevanato Group Full-Year Results Tuesday, 08 March 2022 Lisa Miles: Good morning, and thanks for joining us. With me today is Franco Stevanato, Executive Chairman
0800 138 2636 | service@incommglobal.com Transcript www.incommglobal.com Stevanato Group Full-Year Results Tuesday, 08 March 2022 Lisa Miles: Good morning, and thanks for joining us. With me today is Franco Stevanato, Executive Chairman, Franco Moro, Chief Executive O
Read more →STVNSafe-Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements which include, or may include, words such as "future "expect", "expected", "progress", "intended", "will", "p
Fourth Quarter and Year End 2021 Financial Results March 8, 2021 Exhibit 99.1 Safe-Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements which include, or may include, words such as "future "expect", "expected", "progress", "
Read more →STVNStevanato Group Reports Record 2021 Revenue of 843.9 million - Establishes Full Year 2022 Guidance
Stevanato Group Reports Record 2021 Revenue of 843.9 million - Establishes Full Year 2022 Guidance - PIOMBINO DESE, Italy March 8, 2021 Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceut
Read more →STVNservice@incommglobal.com Transcript www.incommglobal.com Stevanato Q3 Earnings Call Tuesday, 09 November 2021 Lisa Miles Good morning and thank you for joining us. With me today is Franco Stevanato, executive chairman, F
0800 138 2636 | service@incommglobal.com Transcript www.incommglobal.com Stevanato Q3 Earnings Call Tuesday, 09 November 2021 Lisa Miles Good morning and thank you for joining us. With me today is Franco Stevanato, executive chairman, Franco Moro, chief executive offi
Read more →STVN▼ -6.8%on this news
Safe-Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements which include, or may include, words such as "raising", "believe", "potential", "increased", "future", "remai
Third Quarter 2021 Financial Results November 9, 2021 Exhibit 99.1 Safe-Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements which include, or may include, words such as "raising", "believe", "potential", "increased", "futur
Read more →STVN▼ -6.8%on this news
Stevanato Group Reports Strong Third Quarter 2021 Revenue and Financial Results and Updates Full Year 2021 Guidance
Stevanato Group Reports Strong Third Quarter 2021 Revenue and Financial Results and Updates Full Year 2021 Guidance DESE, Italy November 9, 2021 Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the ph
Read more →STVNTranscript 0800 138 2636 | service@incommglobal.com www.incommglobal.com Stevanato Earnings Call Thursday, 19 August 2021 Lisa Miles Good morning and thank you for joining us. With me today, to offer prepared remarks, is
Transcript 0800 138 2636 | service@incommglobal.com www.incommglobal.com Stevanato Earnings Call Thursday, 19 August 2021 Lisa Miles Good morning and thank you for joining us. With me today, to offer prepared remarks, is Franco Stevanato, Executive Chairman, Franco Moro, Chie
Read more →STVN▲ +13.5%on this news· ran to +27% by day 3shared move
Stevanato Group Announces Second Quarter 2021 Financial Results - Establishes Full Year 2021 Guidance
Stevanato Group Announces Second Quarter 2021 Financial Results - Establishes Full Year 2021 Guidance - PIOMBINO DESE, Italy August 19, 2021 Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharm
Read more →STVN▲ +13.5%on this news· ran to +27% by day 3shared move
Forward-Looking Statements This presentation contains certain forward-looking statements which include, or may include, words such as "raising", "believe", "potential", "increased", "future", "remain", "growing", "expect
Second Quarter 2021 Financial Results August 19, 2021 Exhibit 99.1 Forward-Looking Statements This presentation contains certain forward-looking statements which include, or may include, words such as "raising", "believe", "potential", "increased", "future", "remain", "growing
Read more →Competitive Position
How STVN ranks across every disease it competes inCompetitive Position is a premium feature
See how STVN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial